BIOCAUSE HEILEN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 20.9334 million yuan, a decrease of 71.96%
I'm PortAI, I can summarize articles.
BIOCAUSE HEILEN PHARMA released its Q3 2025 report, with operating revenue for the first three quarters amounting to 319 million yuan, a year-on-year decrease of 4.52%. The net profit attributable to the parent company was 20.9334 million yuan, a year-on-year decline of 71.96%; the net profit after deducting non-recurring gains and losses was 543,800 yuan, a year-on-year decrease of 99.14%. The basic earnings per share were 0.05 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments